Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant administration of V260 and DTP-IPV in healthy Japanese infants
2017-000277-37Phase 4
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rotavirus vaccine, live, oral, pentavalent and diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus vaccine in rotaviral diarrhea (2 arms), sponsored by Merck & Co. Primary endpoint: Immunogenicity endpoints.
02
Drugs
rotavirus vaccine, live, oral, pentavalentdiphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus vaccine
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on 2017-000277-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000277-37.